Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer

Table 2

Patients’ characteristics.

	Neoadjuvant treatment	Adjuvant treatment
(patients)	30	56
Age (years), median; range	67; 47–83	62; 44–75
Gender, (%)
Male	20 (67)	36 (64)
Female	10 (33)	20 (36)
5-Fluorouracil, (%)	15 (50)	27 (48)
Capecitabine, (%)	15 (50)	29 (52)
Recurrence during follow-up, (%)
Local recurrence	1 ()	3 ()
Metastasis	9 (30)	15 (27)